Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed ...

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed ...

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for…

Apellis Reports 5-Year Data Showing Syfovre Significantly Delays Geographic Atrophy Progression

Apellis Pharmaceuticals announced new findings from a post hoc analysis of the GALE extension study, revealing that continuous treatment with Syfovre (pegcetacoplan) over 5 years meaningfully slowed the progression of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). According to the analysis, both every-other-month and monthly dosing regimens of Syfovre delayed GA lesion growth by approximately 1.5 years in patients w…